Publication
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (21)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 21
- cancerChronic Myeloid Leukemia, BCR-ABL1 Positivecivic_curation1.00
- drugDasatinibcivic_curation1.00
- drugImatinibcivic_curation1.00
- drugNilotinibcivic_curation1.00
- geneABL1civic_curation1.00
- variantABL1 D276Gcivic_curation1.00
- variantABL1 E255Kcivic_curation1.00
- variantABL1 E255Vcivic_curation1.00
- variantABL1 F317Lcivic_curation1.00
- variantABL1 F359Vcivic_curation1.00
- variantABL1 F486Scivic_curation1.00
- variantABL1 Fusioncivic_curation1.00
- variantABL1 G250Ecivic_curation1.00
- variantABL1 G398Rcivic_curation1.00
- variantABL1 H396Rcivic_curation1.00
- variantABL1 L248Vcivic_curation1.00
- variantABL1 M351Tcivic_curation1.00
- variantABL1 Q252Hcivic_curation1.00
- variantABL1 T315Icivic_curation1.00
- variantABL1 V299Lcivic_curation1.00
- variantABL1 Y253Fcivic_curation1.00
Curated evidence
Evidence citing this paper (52)
50 items per page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 19075254
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ABL1 Y253F + ABL1 Fusion2 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID4341In an in vitro study, a Ba/F3 cell line stably expressing the Y253F mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (IC50: 2.89nM vs… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC | civic |
| Imatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | D | Supports Resistance | 2 | accepted | EID2655A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL p… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC | civic |